albendazole has been researched along with Parkinson Disease in 2 studies
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| " There was a good response to levodopa therapy as well as cysticidal therapy with albendazole, allowing later reduction of levodopa dosage in one patient and complete withdrawal in the other." | 2.71 | Parkinsonism associated with neurocysticercosis. ( Sá, DS; Teive, HA; Troiano, AR; Werneck, LC, 2005) |
| "Rotenone (1." | 1.51 | Hypoxia-inducible factor 1 alpha and nuclear-related receptor 1 as targets for neuroprotection by albendazole in a rat rotenone model of Parkinson's disease. ( Abd El Fattah, MA; Ahmed, LA; El-Sayeh, BM; Kandil, EA; Sayed, RH, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kandil, EA | 1 |
| Sayed, RH | 1 |
| Ahmed, LA | 1 |
| Abd El Fattah, MA | 1 |
| El-Sayeh, BM | 1 |
| Sá, DS | 1 |
| Teive, HA | 1 |
| Troiano, AR | 1 |
| Werneck, LC | 1 |
1 trial available for albendazole and Parkinson Disease
| Article | Year |
|---|---|
Parkinsonism associated with neurocysticercosis.
Topics: Adult; Albendazole; Anthelmintics; Antiparkinson Agents; Brain; Female; Humans; Levodopa; Magnetic R | 2005 |
1 other study available for albendazole and Parkinson Disease
| Article | Year |
|---|---|
Hypoxia-inducible factor 1 alpha and nuclear-related receptor 1 as targets for neuroprotection by albendazole in a rat rotenone model of Parkinson's disease.
Topics: Albendazole; Animals; Behavior, Animal; Cell Death; Cell Survival; Disease Models, Animal; Dopaminer | 2019 |